TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Living Cell Technologies ( (AU:1AI) ) has shared an update.
Algorae Pharmaceuticals Ltd announced successful preclinical validation of its AlgoraeOS v1 platform, which predicts synergistic drug combinations. The validation, conducted by the Victorian Centre for Functional Genomics, confirmed the platform’s ability to identify effective CBD-drug combinations, supporting its use in future drug discovery. This milestone enhances Algorae’s industry positioning by demonstrating the predictive power of its technology, potentially benefiting stakeholders through more targeted and efficient drug development processes.
More about Living Cell Technologies
Algorae Pharmaceuticals Ltd is an AI-enabled pharmaceutical company focused on developing advanced drug-combination prediction platforms. Their primary product, AlgoraeOS, is designed to prioritize drug combinations for potential therapeutic synergy, particularly in the oncology sector.
YTD Price Performance: 50.0%
Average Trading Volume: 3,224,408
Technical Sentiment Signal: Buy
Current Market Cap: A$23.64M
For a thorough assessment of 1AI stock, go to TipRanks’ Stock Analysis page.